In vitro activity of Ro 13-9904, a new beta-lactamase-stable cephalosporin
- 1 February 1981
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 19 (2) , 222-225
- https://doi.org/10.1128/aac.19.2.222
Abstract
The minimal inhibitory concentration (MIC) of Ro 13-9904 against 245 clinical isolates was determined by an agar dilution method. The activity of Ro 13-9904 against most Enterobacteriaceae was similar to that of cefotaxime; it was slightly more active than cefotaxime against Proteus mirabilis, Providencia species, and Serratia marcescens, but slightly less active against Klebsiella species. Ro 13-9904 was twofold more active than cefotaxime and threefold more active than ticarcillin against ticarcillin-susceptible Pseudomonas aeruginosa, with a mean MIC of 7.2 micrograms/ml; isolates highly resistant to ticarcillin were inhibited by a mean MIC of 17.2 micrograms/ml. Ro 13-9904 was fourfold more active than ampicillin against susceptible Haemophilus influenzae and was equally active against beta-lactamase-producing isolates. Ro 13-9904 was highly active against pneumococci and moderately active (MIC, 4 micrograms/ml) against Staphylococcus aureus isolates, whether they were susceptible or resistant to penicillin G. Oxacillin-resistant S. aureus and Streptococcus faecalis were completely resistant to Ro 13-9904 (MIC, greater than 128 micrograms/ml).This publication has 3 references indexed in Scilit:
- In vitro antibacterial activity and susceptibility of the cephalosporin Ro 13-9904 to beta-lactamasesAntimicrobial Agents and Chemotherapy, 1980
- Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporinAntimicrobial Agents and Chemotherapy, 1980
- Novel Method for Detection of β-Lactamases by Using a Chromogenic Cephalosporin SubstrateAntimicrobial Agents and Chemotherapy, 1972